https://www.nasdaq.com/press-release/albireo-increases-2021-bylvaytm-odevixibat-sales-guidance-2022-01-05
https://www.nasdaq.com/press-release/albireo-announces-positive-topline-data-from-phase-1-study-of-a3907-2021-12-16
https://www.nasdaq.com/press-release/albireo-presenting-new-bylvaytm-odevixibat-data-at-naspghan-2021-2021-12-13
https://www.nasdaq.com/press-release/albireo-announces-changes-to-rd-organization-2021-12-09
https://www.nasdaq.com/press-release/albireo-expands-leadership-with-constantine-chinoporos-as-chief-business-officer-2021
https://www.nasdaq.com/press-release/albireo-announces-new-phase-3-data-for-bylvaytm-odevixibat-in-pfic-and-first-reveal
https://www.nasdaq.com/press-release/albireo-to-present-at-upcoming-investor-conferences-2021-11-10
https://www.nasdaq.com/press-release/albireo-reports-q3-financial-results-and-business-update-2021-11-04
https://www.nasdaq.com/press-release/albireo-to-report-third-quarter-2021-financial-results-on-november-4-2021-10-28
https://www.nasdaq.com/press-release/albireo-to-showcase-new-data-at-aasld-the-liver-meetingr-2021-2021-10-15
https://www.nasdaq.com/press-release/cbc-backed-jadeite-medicines-announces-exclusive-licensing-agreement-with-albireo
https://www.nasdaq.com/press-release/albireo-announces-exclusive-licensing-agreement-with-jadeite-medicines-for-bylvaytm
https://www.nasdaq.com/press-release/albireo-recognizes-pfic-awareness-day-2021-2021-10-05
https://www.nasdaq.com/press-release/albireo-announces-bylvayr-odevixibat-now-available-in-germany-2021-09-15
https://www.nasdaq.com/press-release/albireo-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2021-09-08
https://www.nasdaq.com/press-release/albireo-receives-uk-mhra-approval-of-bylvayr-odevixibat-2021-09-08
https://www.nasdaq.com/press-release/albireo-sells-priority-review-voucher-prv-for-%24105-million-2021-09-07
https://www.nasdaq.com/press-release/albireo-to-present-at-upcoming-investor-conferences-2021-09-02
https://www.nasdaq.com/press-release/albireo-reports-q2-financial-results-and-business-update-2021-08-05
https://www.nasdaq.com/press-release/albireo-to-present-at-the-2021-wedbush-pacgrow-virtual-healthcare-conference-2021-08
https://www.nasdaq.com/press-release/albireo-to-report-second-quarter-2021-financial-results-on-august-5-2021-07-29
https://www.nasdaq.com/press-release/albireo-announces-fda-approval-of-bylvaytm-odevixibat-the-first-drug-treatment-for
https://www.nasdaq.com/press-release/albireo-receives-european-marketing-authorization-of-bylvaytm-odevixibat-the-first
https://www.nasdaq.com/press-release/albireo-to-present-at-the-william-blair-biotech-focus-conference-2021-2021-07-08
https://www.nasdaq.com/press-release/albireo-to-present-at-piper-sandlers-virtual-easl-takeaway-day-2021-06-24
https://www.nasdaq.com/press-release/albireo-announces-expanded-phase-3-data-on-bylvaytm-odevixibat-and-a3907-at-upcoming
https://www.nasdaq.com/press-release/albireo-to-showcase-new-data-at-the-easl-international-liver-congresstm-2021-2021-06
https://www.nasdaq.com/press-release/new-phase-3-data-at-wcpghan-show-long-term-safety-tolerability-and-treatment-benefits
https://www.nasdaq.com/press-release/albireo-to-present-at-upcoming-jefferies-and-william-blair-virtual-investor
https://www.nasdaq.com/press-release/albireo-receives-positive-chmp-opinion-for-bylvaytm-odevixibat-for-treatment-of-0
https://www.nasdaq.com/press-release/albireo-receives-positive-chmp-opinion-for-bylvaytm-odevixibat-for-treatment-of
https://www.nasdaq.com/press-release/albireo-to-showcase-new-data-at-6th-world-congress-of-pediatric-gastroenterology
https://www.nasdaq.com/press-release/albireo-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2021-05-07
https://www.nasdaq.com/press-release/albireo-reports-q1-financial-results-and-business-update-2021-05-06
https://www.nasdaq.com/press-release/albireo-to-report-first-quarter-2021-financial-results-on-may-6-2021-04-29
https://www.nasdaq.com/press-release/albireo-expands-leadership-with-joan-connolly-as-chief-technology-officer-2021-04-13
https://www.nasdaq.com/press-release/albireo-to-participate-in-the-needham-20th-annual-virtual-healthcare-conference-2021
https://www.nasdaq.com/press-release/albireo-announces-first-patients-dosed-in-two-new-studies-2021-03-25
https://www.nasdaq.com/press-release/albireo-spotlights-global-patient-communities-on-rare-disease-day-2021-02-26
https://www.nasdaq.com/press-release/albireo-reports-q4-and-year-end-2020-financial-results-and-business-update-2021-02-25
https://www.nasdaq.com/press-release/albireo-to-participate-in-cowen-and-h.c.-wainwright-global-investor-conferences-2021
https://www.nasdaq.com/press-release/albireo-to-report-q4-and-year-end-2020-financial-results-on-february-25-2021-02-18
https://www.nasdaq.com/press-release/albireo-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2021-02-17
https://www.nasdaq.com/press-release/albireo-presents-odevixibat-commercialization-road-to-%241-billion-2021-02-11
https://www.nasdaq.com/press-release/albireo-announces-u.s.-fda-acceptance-of-new-drug-application-for-odevixibat-2021-01
https://www.nasdaq.com/press-release/albireo-recognizes-international-alagille-syndrome-awareness-day-2021-2021-01-22
https://www.nasdaq.com/press-release/albireo-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2021-01-14
https://www.nasdaq.com/press-release/albireo-to-host-virtual-investor-commercial-day-2021-2021-01-07
https://www.nasdaq.com/press-release/albireo-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2021-01-06
https://www.nasdaq.com/press-release/albireo-to-participate-in-h.c.-wainwright-bioconnect-and-lifesci-advisors-investor
https://www.nasdaq.com/press-release/albireo-initiates-global-phase-3-clinical-trial-of-odevixibat-in-alagille-syndrome
https://www.nasdaq.com/press-release/albireo-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2020-12-11
https://www.nasdaq.com/press-release/albireo-submits-for-u.s.-fda-and-ema-product-approval-of-once-daily-odevixibat-for
https://www.nasdaq.com/press-release/new-phase-3-data-at-aasld-show-durable-response-to-odevixibat-in-a-rare-pediatric
https://www.nasdaq.com/press-release/albireo-to-participate-in-jefferies-and-piper-sandler-virtual-investor-conferences
https://www.nasdaq.com/press-release/albireo-reports-q3-2020-financial-results-and-provides-business-update-2020-11-05
https://www.nasdaq.com/press-release/albireos-odevixibat-pfic-phase-3-results-accepted-for-aasld-late-breakers-2020-11-02
https://www.nasdaq.com/press-release/albireo-announces-presentations-at-naspghan-2020-annual-meeting-2020-10-23
https://www.nasdaq.com/press-release/albireo-recognizes-pfic-awareness-day-2020-2020-10-05
https://www.nasdaq.com/press-release/albireo-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2020-10-02
https://www.nasdaq.com/press-release/albireo-prices-public-offering-of-4000000-shares-of-common-stock-2020-09-09
https://www.nasdaq.com/press-release/albireo-announces-proposed-public-offering-of-3000000-shares-of-common-stock-2020-09
https://www.nasdaq.com/press-release/albireo-phase-3-trial-meets-both-primary-endpoints-for-odevixibat-in-pfic-2020-09-08
https://www.nasdaq.com/press-release/albireo-to-announce-topline-results-from-pedfic-1-phase-3-trial-of-odevixibat-on
https://www.nasdaq.com/press-release/albireo-reports-topline-results-from-phase-2-trial-of-elobixibat-in-nafld-nash-2020
https://www.nasdaq.com/press-release/albireo-reports-q2-2020-financial-results-and-provides-business-update-2020-08-06
https://www.nasdaq.com/press-release/albireo-to-present-at-the-william-blair-biotech-focus-conference-2020-2020-07-30
https://www.nasdaq.com/press-release/albireo-to-report-q2-2020-financial-results-on-august-6-2020-07-30
https://www.nasdaq.com/press-release/albireo-launches-expanded-access-program-for-odevixibat-for-patients-in-the-u.s.
https://www.nasdaq.com/press-release/albireo-enrolls-first-patient-in-phase-3-clinical-trial-of-odevixibat-in-biliary
https://www.nasdaq.com/press-release/albireo-to-host-key-opinion-leader-call-on-clinical-outcome-assessments-2020-06-10
https://www.nasdaq.com/press-release/albireo-announces-two-financing-transactions-to-extend-cash-runway-into-the-beginning
https://www.nasdaq.com/press-release/albireo-to-present-at-2020-jefferies-virtual-healthcare-conference-2020-05-26
https://www.nasdaq.com/press-release/albireo-reports-q1-2020-financial-results-and-provides-business-update-2020-05-07
https://www.nasdaq.com/press-release/albireo-to-report-first-quarter-2020-financial-results-on-may-7-2020-04-30
https://www.nasdaq.com/press-release/albireo-to-present-at-19th-annual-needham-healthcare-conference-2020-04-07
https://www.nasdaq.com/press-release/albireo-completes-enrollment-in-phase-2-study-of-elobixibat-in-nash-nafld-2020-03-10
https://www.nasdaq.com/press-release/albireo-reports-fourth-quarter-and-year-end-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/albireo-recognizes-rare-disease-day-and-supports-global-effort-to-reframe-rare-by
https://www.nasdaq.com/press-release/albireo-to-present-at-cowen-and-company-40th-annual-health-care-conference-2020-02-26
https://www.nasdaq.com/press-release/albireo-to-report-fourth-quarter-and-year-end-2019-financial-results-on-march-2-2020
https://www.nasdaq.com/press-release/albireo-announces-closing-of-%2446-million-public-offering-including-exercise-in-full
https://www.nasdaq.com/press-release/albireo-prices-%2440-million-public-offering-of-common-stock-2020-01-29
https://www.nasdaq.com/press-release/albireo-announces-proposed-public-offering-of-common-stock-2020-01-29
https://www.nasdaq.com/press-release/albireo-achieves-significant-milestones-for-odevixibat-across-multiple-diseases-2020
https://www.nasdaq.com/press-release/albireo-joins-with-alagille-syndrome-community-in-celebrating-first-international
https://www.nasdaq.com/press-release/albireo-to-present-at-the-jefferies-2019-london-healthcare-conference-2019-11-14
https://www.nasdaq.com/press-release/albireo-reports-third-quarter-2019-financial-results-and-provides-business-update
